Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world bimekizumab study in axial spondyloarthritis
NL-OMON58059Phase 4Recruiting
- Sponsor
- UCB
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimekizumab in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by UCB. Primary endpoint: Achievement of ASDAS low disease activity at Week 52. Started Nov 2025; status: recruiting.
02
Drugs
bimekizumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON58059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58059.